ClinicalTrials.gg
TerminatedNCT03596424Updated Oct 22, 2026

Dexmedetomidine and Ketamine in VATS Surgery

An interventional study of Ketamine Hydrochloride and Dexmedetomidine Hydrochloride in Postoperative Pain and Opioid Use, sponsored by Ciusss de L'Est de l'Île de Montréal. Terminated at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Ciusss de L'Est de l'Île de Montréal · Not applicable, Interventional, and Prevention

How we know

Why this study was terminated
Not enough funding. recruitment less than anticipated

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2018, registered May 2018).
Updated Oct 22, 2026Now TerminatedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies testing ketamine in Pain, Postoperative — 9 open to participants now, 11 under way, 3 of them phase 3. Ketamine · Pain, Postoperative.

Enrollment
76th of 92
40 · median 78
Started
2018
with 2 others
No phase
17 of 92
2 open now
Registered
51st of 92
by date

Among the 92 studies testing ketamine in Pain, Postoperative, this one is the 76th largest by enrollment, is one of 3 that started in 2018, is one of 17 with no phase, and was the 51st registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

9 of the 92 studies testing ketamine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies testing ketamine in Pain, Postoperative, or all of them as a file.
02

Study summary

Postoperative pain after VATS surgery is significant and associated with moderate to high post operative morphine requirements, which can cause opioid related side effects and delay postoperative recovery. To reduce this requirement, multimodal analgesia with non opioid medication such as dexmedetomidine and ketamine can be used. These drugs have demonstrated significant opioid-sparing properties after various types of surgeries. However, very little is known about their ability to do so in VATS surgery. Also, their relative opioid-sparing properties have not been compared, and it is not known whether their combined use can lead to an additional opioid-sparing effect. The primary goal of this study will be to determine the impact of a combined intra operative infusion of ketamine and dexmedetomidine on postoperative morphine requirements in patients undergoing elective VATS, compared to both these drugs infused separately.

The hypothesis is that this combined infusion will lead to a 30% further reduction in morphine requirements, 24h after surgery, compared to both these drugs infused separately.

Read the detailed description

Video-assisted thoracic surgery (VATS) for pulmonary resection is associated with less tissue trauma, less impairment in lung function, and reduced postoperative pain compared with thoracotomy, although many patients continue to report significant acute postoperative pain. If not well-controlled, postoperative thoracic pain can lead to splinting and inadequate recovery of pulmonary function.

Enhancing the quality of postoperative analgesia while reducing intra and postoperative opioid requirements is an important issue that has been one of the main focus of Enhanced Recovery After Surgery (ERAS) protocols. Indeed, the key factors that delay postoperative recovery include parenteral opioids and bed rest and immobility secondary to postoperative pain. While opioids are effective at treating even severe pain, their use is associated with dose-related adverse effects such as respiratory depression, sedation, postoperative nausea and vomiting, urinary retention, ileus, opioid-induced hyperalgesia and chronic postoperative pain. More importantly, opioids depress host immunity and neuroendocrine function and may negatively affect cancer recurrence and survival after lung cancer surgery.

Hence, given the importance of good postoperative analgesia and the significance of opioid-related adverse effects, the reduction of opioid requirements and postoperative pain through multimodal analgesia is an important matter. Focusing on this goal, the ERAS protocols have shown great efficacy in improving patient's care after colorectal surgery and they are now being applied to pancreatic, ENT, bariatric, urologic and many more major surgeries.

It is probably only a matter of time before ERAS protocols are applied to VATS surgery; however, the optimal way of providing postoperative analgesia after VATS has not yet been determined, unlike colorectal surgery. Indeed, thoracic epidural analgesia, single-shot and continuous paravertebral and intercostal nerve blocks and patient-controlled intravenous analgesia have all been evaluated, and none of these has consistently emerged as being superior to the others or to intravenous analgesia. Thoracic epidural analgesia provides effective pain control for thoracotomy but its benefits following thoracoscopy are not uniform. Furthermore, the risks of sympathectomy-induced hypotension and neurologic injury from epidural hematoma may not be justified considering the lesser postoperative pain and impairment in pulmonary function compared to thoracotomy. Continuous paravertebral blocks are an effective alternative to epidural analgesia although their performance may be challenging and time consuming, and catheters may be difficult to thread or get accidentally removed, leading to block failure. Furthermore, as for epidural analgesia, paravertebral catheter placement is contra-indicated in patients with impaired coagulation and/or infection. Single-shot intercostal and paravertebral blocks are less invasive although their benefit is restricted to the first twelve postoperative hours.

Moreover, none of these regional anesthesia techniques can treat the ipsilateral shoulder pain that is often associated with VATS, and opioid analgesia might still be required.

An intravenous opioid patient-controlled analgesia combined to multimodal analgesia with acetaminophen and non-steroidal anti-inflammatoy drug (NSAID) is commonly used in many institutions and has shown to provide adequate and effective postoperative analgesia. However, significant acute postoperative pain and moderate to high opioid consumption are still reported after VATS. There is definitely some place for improvement, which could come from other non-opioid analgesic adjuncts such as ketamine and/or dexmedetomidine.

Ketamine is an anesthetic drug that has well-known analgesic properties due to its ability to block NMDA receptors. An intraoperative bolus followed with a low-dose infusion reduces postoperative opioid requirements by 30-40%, without causing significant side effects. Similarly, dexmedetomidine is a centrally acting α2-agonist with sedating and analgesic properties. When used intra-operatively, it significantly reduces hypnotics and opioids requirements, decreases median pain scores and reduces postoperative morphine consumption by approximately 30%. These systematic reviews seem to indicate a greater morphine-sparing effect from ketamine compared to dexmedetomidine although this has not been evaluated thoroughly. Indeed, only one study compared ketamine's morphine-sparing effects to that of dexmedetomidine, in patients undergoing spine surgery. Both infusions were started postoperatively and provided significant morphine sparing effects compared to placebo. Ketamine's morphine-sparing effect appeared greater than that of dexmedetomidine, although this was not statistically significant, as this study was not powered for that outcome. Hence, their morphine-sparing effect might be different but this difference is likely small. Their impact on postoperative opioid requirement after VATS surgery has not been studied, even though it could be highly beneficial, not only for the reduction of postoperative opioid requirements but for the reduction of chronic postoperative pain.

Another interesting reason for using these analgesic adjuvants for intra operative analgesia is their ability to prevent chronic post operative pain.

More interesting would be to investigate whether their combined use leads to greater morphine-sparing effect. Indeed, although their combination for paediatric procedural sedation is well described, the impact of a combined dexmedetomidine-ketamine intraoperative infusion on postoperative analgesia and opioid requirements has not been evaluated.

Study outcome and hypothesis

The primary goal of this study will be to determine the impact of a combined intra operative infusion of ketamine and dexmedetomidine on postoperative morphine requirements in patients undergoing elective VATS, compared to both these drugs infused separately.

The hypothesis is that this combined infusion will lead to a 30% further reduction in morphine requirements, 24h after surgery, compared to both these drugs infused separately.

Secondary outcomes will be to evaluate the impact of a combined dexmedetomidine-ketamine infusion on:

  • Postoperative pain scores at rest and after coughing at 24 and 48 h postoperatively;
  • Cumulative morphine consumption 48 h after surgery;
  • Intraoperative fentanyl requirements, determined using the NoL index (see methodology section, page);
  • Time to chest tube removal and time to hospital discharge;
  • Proportion of patients with persistent pain three months after surgery;
  • Incidence of ketamine-induced psychomimetic side effects in the postoperative period
  • Incidence of intraoperative bradycardia \<50 beats/min compared to intraoperative infusions of ketamine only and dexmedetomidine only.

METHODOLOGY

Study design

This will be a prospective, randomized, double blind study.

Population

Patients undergoing elective VATS and receiving an opioid intravenous patient-controlled analgesia (PCA) combined with acetaminophen and NSAID for postoperative analgesia.

Duration of study

1 year

Sample size Postoperative cumulative morphine consumption 24h after surgery in our institution has been determined by reviewing the files of 50 patients who underwent VATS surgery and received a PCA combined to acetaminophen and NSAID for postoperative analgesia. These patients used an average (standard deviation (SD)) of 39.5 (17.3) mg of morphine.

Considering an opioid-sparing effect of 30% from dexmedetomidine and ketamine alone, a mean morphine consumption of 27.7(11) mg can be expected in the ketamine and dexmedetomidine groups.

A 30% further reduction in opioid requirement from combining ketamine to dexmedetomidine will be considered significant.

Thus, a sample size of 37 patients per group would give us 80% power to detect such a difference, alpha 0.05.

03

Conditions studied

  • Postoperative Pain
  • Opioid Use

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-80 years old
  • American Society of Anesthesiology physical status I-III
  • Elective Video-Assisted Thoracic Surgery for pulmonary resection

Exclusion criteria

Exclusion Criteria:

  • Patients for which a regional anesthesia technique is planned for postoperative analgesia.
  • Patients taking beta-blockers preoperatively.
  • Patients with chronic pain taking >60 mg morphine PO daily (or its equivalent).
  • Patients taking pregabalin, gabapentin, amitryptillin, nortryptillin and/or duloxetin.
  • Documented allergy to ketamine and/or dexmedetomidine.
  • Pregnancy
  • Inability to give
  • Linguistic barrier.
  • Patient refusal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Ketamine hydrochloride

    Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;

    Drug: Ketamine Hydrochloride

  • Active comparator
    dexmedetomidine hydrochloride

    Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline

    Drug: Dexmedetomidine Hydrochloride

  • Active comparator
    dexmedetomidine hydrochloride and ketamine hydrochloride

    Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine

    Combination Product: dexmedetomidine Hydrochloride and Ketamine Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Day 1 Postoperative morphine requirement

    Cumulative dose of morphine used by the patient

    Time frame: Day 1

Secondary outcomes

  1. day 2 Postoperativve morphine requirement

    cumulative dose of morphine used by the patient

    Time frame: day 2

  2. Pain score at rest 24h

    Pain score (Verbal Numeric Scale (0-10) at rest

    Time frame: day 1

  3. Pain score at rest 48h

    Pain score (Verbal Numeric Scale (0-10) at rest

    Time frame: day 2

  4. Pain score at cough 24h

    Pain score (Verbal Numeric Scale (0-10) at cough

    Time frame: day 1

  5. Pain score at cough 48h

    Pain score (Verbal Numeric Scale (0-10) at cough

    Time frame: day 2

  6. intraoperative fentanyl requirement

    intraoperative dose of fentanyl used to treat intraoperative pain

    Time frame: for incision to wound closure

  7. chest tube removal

    time (days) for chest tube removal after surgery

    Time frame: 1 week

  8. chronic postoperative pain

    patients reporting persistent post operative pain

    Time frame: 3 months

07

Study locations

1 site
  • Ciusss
    Montreal, Quebec H1T2M4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Dec 2025, 94 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2018
First posted
Jul 23, 2018
StartActual
Feb 1, 2018
Primary completionActual
Dec 1, 2025
CompletionActual
Jul 1, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Not enough funding. recruitment less than anticipated
changed Oct 22, 2026
Sites
1 site added, 1 site removed
Show site
  • Ciusss · Montreal, Canada
Show 1 removed
  • Ciusss · Montréal, Canada
Oct 22, 2026
Enrollment
120 (estimated)→40 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Terminated
    Why stopped Not enough funding. recruitment less than anticipated
    1 site added, 1 site removed
    Show site
    • Ciusss · Montreal, Canada
    Show 1 removed
    • Ciusss · Montréal, Canada
    Enrollment 120 (estimated)→40 (actual)
    + 5 other changes: verification date, date precision, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03596424
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Responsible party
Veronique Brulotte (Dr, Maisonneuve-Rosemont Hospital) — Principal investigator
First posted
Jul 23, 2018
Start date
Feb 1, 2018
Primary completion
Dec 1, 2025
Completion
Jul 1, 2026
Last update
Oct 22, 2026

Study contacts

Veronique Brulotte, MD
principal investigator · Ciusss de L'Est de l'Île de Montréal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketamine · Dexmedetomidine

Start the discussion